Albert Llado Plarrumani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4821128/publications.pdf

Version: 2024-02-01

104 papers	3,933 citations	147801 31 h-index	133252 59 g-index
116 all docs	116 docs citations	116 times ranked	6317 citing authors

#	Article	IF	Citations
1	Cost-effectiveness of Alzheimerâ€™s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 243-252.	3.2	8
2	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimerâ€™s disease. Journal of Neurology, 2022, 269, 2573-2583.	3.6	6
3	Errorless Learning Therapy in Semantic Variant of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 79, 415-422.	2.6	6
4	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	4.1	9
5	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
6	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
7	Spanish-dementia knowledge assessment scale (DKAS-S): psychometric properties and validation. BMC Geriatrics, 2021, 21, 302.	2.7	8
8	Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration. Cells, 2021, 10, 1174.	4.1	3
9	Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 705989.	3.4	9
10	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 32, 102804.	2.7	28
11	Going round in circlesâ€”The Papez circuit in Alzheimer's disease. European Journal of Neuroscience, 2021, 54, 7668-7687.	2.6	22
12	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, .	0.8	4
13	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
14	ALTOIDAâ€iADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, e057982.	0.8	1
15	Impact of COVIDâ€19 pandemic in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2021, 17, e052114.	0.8	0
16	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.8	47
17	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
18	Distinct neuropsychological presentation and progression between earlyâ€and lateâ€onset Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e036809.	0.8	1

#	Article	IF	Citations
19	MRI decline pattern in early onset MCI due to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037405.	0.8	0
20	Four yearsâ€™ experience in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2020, 16, e037911.	0.8	0
21	Evolution of clinicalâ€pathological correlation of earlyâ€onset Alzheimer's disease: 1994â€“2009 vs 2010â€“2017. Alzheimer's and Dementia, 2020, 16, e041388.	0.8	0
22	An ABCA7 partial deletion and a GRN variant in a semantic variant of primary progressive aphasia patient. Alzheimer's and Dementia, 2020, 16, e042483.	0.8	1
23	Differential gene expression in genetic and earlyâ€onset Alzheimerâ€™s disease in two biological samples: Brain tissue and lymphoblastoid cell lines. Alzheimer's and Dementia, 2020, 16, e042671.	0.8	0
24	Functional network alterations in earlyâ€onset Alzheimerâ€™s disease studied with restingâ€state fMRI. Alzheimer's and Dementia, 2020, 16, e043307.	0.8	0
25	Mitochondrial Dysfunction: A Common Hallmark Underlying Comorbidity between sIBM and Other Degenerative and Age-Related Diseases. Journal of Clinical Medicine, 2020, 9, 1446.	2.4	4
26	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	29
27	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 1575-1583.	2.6	12
28	Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013.	3.6	22
29	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. Neurobiology of Aging, 2020, 93, e1-e9.	3.1	11
30	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. NeuroImage: Clinical, 2019, 23, 101927.	2.7	29
31	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1559-1565.	3.7	6
32	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). Neurobiology of Aging, 2019, 84, 236.e9-236.e15.	3.1	7
33	Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings. Journal of Neurology, 2019, 266, 2396-2405.	3.6	22
34	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
35	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. Neurobiology of Aging, 2019, 81, 1-8.	3.1	5
36	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45

#	Article	IF	Citations
37	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimerâ€™s disease. NeuroImage: Clinical, 2019, 22, 101777.	2.7	29
38	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. Sleep, 2019, 42, .	1.1	30
39	Clinical applicability of diagnostic biomarkers in earlyâ€onset cognitive impairment. European Journal of Neurology, 2019, 26, 1098-1104.	3.3	20
40	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
41	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	3.8	115
42	Structural Connectivity Alterations Along the Alzheimerâ€™s Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-Î² and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	2.6	25
43	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
44	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
45	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
46	P2â€347: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDPâ€43 PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P819.	0.8	0
47	P1â€146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLYâ€ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P332.	0.8	0
48	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
49	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
50	P1â€432: REGIONAL PATTERNS OF 18Fâ€FLORBETABEN UPTAKE IN PRESENILIN 1ÂMUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.8	0
51	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
52	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
53	The hippocampal longitudinal axisâ€”relevance for underlying tau and TDP-43 pathology. Neurobiology of Aging, 2018, 70, 1-9.	3.1	21
54	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18

#	Article	IF	Citations
55	The APOE Îµ4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	2.4	36
56	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
57	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
58	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
59	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
60	CSF sAPPÎ², YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.1	100
61	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology, 2017, 82, 419-428.	5.3	161
62	Frontotemporal Dementia Caused by the P301L Mutation in the<i> MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
63	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
64	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimerâ€™s Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	4.0	119
65	[P4â€“505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. Alzheimer's and Dementia, 2017, 13, P1533.	0.8	0
66	[P2â€“355]: CSF STREM2, BUT NOT YKLâ€40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P758.	0.8	0
67	[P2â€“410]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P789.	0.8	0
68	[P4â€“214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. Alzheimer's and Dementia, 2017, 13, P1348.	0.8	0
69	[P1â€“413]: VISUAL PATTERNS OF FLORBETABEN UPTAKE IN PRESENILIN 1 MUTATION CARRIERS. Alzheimer's and Dementia, 2017, 13, P435.	0.8	0
70	Sporadic MM2â€thalamicâ€‰+â€‰cortical Creutzfeldtâ€Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement in vivo. Neuropathology, 2016, 36, 199-204.	1.2	11
71	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	2.6	17
72	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	2.6	17

#	Article	IF	Citations
73	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimerâ€™s Disease. , 2016, 12, P8-P8.		0
74	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	7.7	83
75	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	3.1	5
76	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.8	86
77	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	3.1	9
78	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	3.1	54
79	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	4.0	15
80	Rare Variants inPLD3Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
81	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
82	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	3.1	30
83	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
84	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
85	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 919-927.	2.6	32
86	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 297-304.	1.3	82
87	Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics, 2014, 15, 145-149.	1.4	12
88	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 901-908.	2.6	102
89	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
90	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93

#	Article	IF	Citations
91	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid Î² protein 42 levels. Neurobiology of Aging, 2014, 35, 2671-2680.	3.1	72
92	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	2.6	53
93	P1-253: WHITE MATTER CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE: AN MRI DIFFUSION TENSOR IMAGING STUDY. , 2014, 10, P399-P400.		0
94	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	2.5	407
95	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. Journal of Alzheimer's Disease, 2012, 31, 581-591.	2.6	31
96	PICOGEN: experiencia de 5 aÃ±os de un programa de asesoramiento genÃ©tico en demencia. NeurologÃa, 2011, 26, 143-149.	0.7	28
97	Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology, 2011, 76, 1720-1725.	1.1	123
98	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	2.6	136
99	A novel PSEN1 mutation (K239N) associated with Alzheimerâ€™s disease with wide range age of onset and slow progression. European Journal of Neurology, 2010, 17, 994-996.	3.3	21
100	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
101	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. Journal of Neurology, 2008, 255, 488-494.	3.6	40
102	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. Neuroscience Letters, 2007, 424, 61-65.	2.1	14
103	Changes in the sympathetic skin response after thoracoscopic sympathectomy in patients with primary palmar hyperhidrosis. Clinical Neurophysiology, 2005, 116, 1348-1354.	1.5	9
104	Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology, 2004, 63, 1947-1949.	1.1	40